Investigational drug · Phase 2
CGT4859
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CGT4859"
First trial start
2025
Jan 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CGT4859", any sponsor or status.
Conditions studied
As listed on its trial records.
- Intrahepatic Cholangiocarcinoma (Icc)
- Cholangiocarcinoma
- Other Solid Tumors, Adult
- FGFR2 Gene Fusion/Rearrangement
- FGFR2 Gene Amplification
- FGFR2 Gene Short Variants
- FGFR3 Gene Fusion/Rearrangement
- FGFR3 Gene Amplification
- FGFR3 Gene Short Variants
- FGFR2 Genetic Alterations
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CGT4859" as an intervention, largest first.
- A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid TumorsActive, not recruiting
Cogent Biosciences, Inc.Industry
NCT06777316 · 110 participants (planned) · Start Jan 22, 2025 · Primary completion Mar 2027
Drug: CGT4859 · For: Intrahepatic Cholangiocarcinoma (Icc); Cholangiocarcinoma; Other Solid Tumors, Adult and 9 more
Sites: Palo Alto, California; Jacksonville, Florida; Tampa, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Intrahepatic Cholangiocarcinoma (Icc)
- tinengotinibTT-00420Phase 36 trials
TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)
- ICP-192Phase 21 trial
Beijing InnoCare Pharma Tech Co., Ltd. · Intrahepatic Cholangiocarcinoma (ICC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.